EPISODE · Nov 26, 2025 · 4 MIN
Long-term Efficacy and Safety of Lerodalcibep in the Open-label 72-week Extension Study of Subjects Previously on Inclisiran or Lerodalcibep in the LIBerate-VI Trial - report from AHA 2025
from Medical Digest & Congress Report · host Medical Congress News
Dr. Evan A Stein shares his insights on the emerging opportunities for managing cardiometabolic syndrome at AHA Scientific Sessions 2025.Video: https://medicaldigest.org/scientific-contents/interview:long-term-efficacy-and-safety-lerodalcibep-open-label-72-week-extension-study-subjects-previously-inclisiran-or-lerodalcibep-liberate-vi-trial
Embed this episode
Ready to play
Long-term Efficacy and Safety of Lerodalcibep in the Open-label 72-week Extension Study of Subjects Previously on Inclisiran or Lerodalcibep in the LIBerate-VI Trial - report from AHA 2025
No transcript for this episode yet
Similar Episodes
No similar episodes found.